Sugi Holdings Co (7649) AI Stock Analysis

• Market Cap: ¥567.69B
• Dividend Yield: 1.08%
• Average Volume (3M): 797.22K
• Price to Earnings (P/E): 21.2
• Beta (1Y): 0.21
• Revenue Growth: 17.94%
• EPS Growth: 18.31%
• Country: JP
• Employees: 8,724
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 143.70
• Shares Outstanding: 189,992,510
• 10 Day Avg. Volume: 695,320
• 30 Day Avg. Volume: 797,223
• PEG Ratio: 1.16
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,499.78
• Price Target Upside: 16.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Sugi Holdings Co demonstrates strong financial performance with solid growth and stability across income, balance sheet, and cash flow metrics. The technical analysis supports a positive market sentiment, though the valuation is moderate, reflecting a balanced investment opportunity. The overall score is driven primarily by the company's robust financial foundation and positive technical indicators.

Sugi Holdings Co Business Overview & Revenue Model

Company Description

Sugi Holdings Co.,Ltd. operates drugstores in Japan. It also provides visiting nursing services and home care support services. As of June 1, 2019, the company operated 1,190 stores. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.

How the Company Makes Money

Sugi Holdings Co., Ltd. generates revenue primarily through the sale of pharmaceutical products, over-the-counter drugs, and a diverse range of health and beauty items. The company's pharmacies are strategically located to serve a broad customer base, providing both prescription fulfillment services and retail sales. Revenue streams are bolstered by its ability to attract repeat customers through loyalty programs and personalized healthcare services. Additionally, Sugi Holdings benefits from economies of scale and strong supplier relationships, which contribute to its profitability. The company also explores opportunities for expansion and diversification to drive growth, including partnerships with healthcare providers and leveraging technology to enhance customer experience.

Sugi Holdings Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
744.48B	667.65B	625.48B	602.51B	541.96B
	Gross Profit
228.84B	202.52B	191.49B	181.29B	162.18B
	EBIT
36.62B	31.66B	32.14B	33.70B	29.76B
	EBITDA
46.24B	44.02B	43.41B	43.64B	38.17B
	Net Income Common Stockholders
21.98B	19.01B	19.39B	21.12B	20.78B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
47.43B	70.64B	71.83B	95.84B	91.35B
	Total Assets
390.56B	351.89B	334.76B	345.93B	313.76B
	Total Debt
837.00M	1.95B	2.31B	2.33B	1.61B
	Net Debt
-42.59B	-60.69B	-60.52B	-84.51B	-79.74B
	Total Liabilities
157.20B	135.36B	120.87B	145.30B	131.01B
	Stockholders Equity
233.36B	216.54B	213.89B	200.63B	182.75B
Cash Flow		Free Cash Flow
6.34B	16.77B	-16.20B	12.46B	24.97B
	Operating Cash Flow
39.04B	38.28B	7.17B	34.03B	45.35B
	Investing Cash Flow
-30.98B	-23.26B	-23.89B	-29.25B	-18.42B
	Financing Cash Flow
-5.28B	-14.21B	-5.29B	-5.27B	-4.89B

Sugi Holdings Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3012.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7649, the sentiment is Positive. The current price of 3012 is above the 20-day moving average (MA) of 2944.28, above the 50-day MA of 2846.09, and above the 200-day MA of 2610.87, indicating a bullish trend. The MACD of 42.36 indicates Negative momentum. The RSI at 57.87 is Neutral, neither overbought nor oversold. The STOCH value of 89.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7649.

Sugi Holdings Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7649	74 Outperform	¥567.69B	21.22	10.45%	1.08%	17.94%	18.31%
2692	74 Outperform	¥111.77B	13.62		1.59%	4.00%	24.34%
3141	74 Outperform	¥525.82B	34.91		1.43%	5.56%	-43.53%
7630	73 Outperform	¥150.36B	47.39		1.70%	10.64%	18.07%
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%

Sugi Holdings Co Corporate Events

Sugi Holdings Announces Merger to Strengthen Healthcare Strategy

Sugi Holdings Co., Ltd. announced an absorption-type merger where Sugi Pharmacy Co., Ltd., a consolidated subsidiary, will absorb I&H Co., Ltd. This merger aims to enhance cooperation within the group and achieve synergy effects, improving productivity and corporate value. The merger is part of Sugi Holdings’ strategy to strengthen its position in the healthcare market, particularly in preventive medicine and specialty pharmaceuticals, without materially affecting the company’s consolidated results.

SUGI Holdings Announces Leadership Change at Subsidiary

SUGI Holdings Co., Ltd. announced a change in the representative director of its subsidiary, Sugi Pharmacy Co., Ltd., effective March 1, 2025. Shinya Sugiura will assume the role, bringing extensive experience from various leadership positions within the company’s group, potentially impacting the strategic direction and operations of Sugi Pharmacy.

Sugi Holdings Co. Sees Significant Sales Growth and Expansion in January

Sugi Holdings Co. reported a 5.9% increase in existing store sales for January, driven by a 6.3% rise in the Sugi Pharmacy Business and a slight 0.2% increase in the Japan Business. On an all-store basis, total sales grew by 20.4%, with the Sugi Pharmacy Business achieving an 11.6% increase. The company opened nine new stores and closed one, resulting in a total of 2,182 stores by the end of January, continuing its strategic expansion in the retail pharmacy sector.